HCA
PTGX icon

Horan Capital Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Horan Capital Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1
Closed – – 285
2019
Q3 		$0 Buy
+1
New +$13 ﹤0.01% 285

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Horan Capital Advisors's PTGX Position: Q4 2019 in Review

Horan Capital Advisors sold out of Protagonist Therapeutics (PTGX) in Q4 2019, closing a stake of 1 share.

Horan Capital Advisors first reported a position in PTGX in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 81 funds tracked by Wall St. Rank hold PTGX as of Q4 2019.

  • Horan Capital Advisors reported no remaining Protagonist Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Horan Capital Advisors sold 1 Protagonist Therapeutics share in Q4 2019.
  • Horan Capital Advisors first reported a position in Protagonist Therapeutics in Q3 2019 and held it in 1 quarter.
  • Horan Capital Advisors's Protagonist Therapeutics position peaked at $0 in Q3 2019.
  • 81 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2019.

Based on Horan Capital Advisors's 13F filing for Q4 2019, filed 5 Feb 2020.